TG Therapeutics, Inc. TGTX

TGTX Company Overview

TG Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for B-cell diseases, particularly autoimmune and hematologic conditions. The company operates within the biotechnology and specialty pharmaceutical industries and is primarily known for its work in multiple sclerosis (MS) and B-cell malignancies. Its core commercial product is Briumvi (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for relapsing forms of multiple sclerosis. Historically, the company also developed oncology-focused therapies targeting chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

TG Therapeutics’ principal revenue driver is product sales associated with Briumvi, alongside collaboration-related revenue and prior licensing arrangements. The company has positioned itself around differentiated B-cell targeting therapies, emphasizing shorter infusion times and commercial specialization in neurology. Founded in 1993 and later reoriented through strategic acquisitions and licensing activities, TG Therapeutics evolved from an oncology-centered biotechnology company into a commercial-stage MS-focused enterprise following regulatory approvals and pipeline reprioritization.